Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | MPN updates: personalized prognostication, novel treatments & more

Ruben Mesa • 18 Jan 2019
ASH 2018
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Azacitidine Decitabine Fedratinib Imetelstat Momelotinib Pacritinib Peginterferon alfa-2a PRM-151 Ruxolitinib Thalidomide

Ruben Mesa, MD, of the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares his view on the highlights for myeloproliferative neoplasms (MPNs), including novel treatments, outlooks, and individualized prognostication, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Ruben Mesa

Time without transfusion reliance: quantifying transfusion independence in myelofibrosis 3:11
Time without transfusion reliance: quantifying transfusion independence in myelofibrosis
Ruben Mesa • 23 Aug 2025
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs 2:12
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs
Ruben Mesa • 23 Aug 2025
The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
The role of non-pharmacological interventions in reducing the symptom burden in MPNs 1:39
The role of non-pharmacological interventions in reducing the symptom burden in MPNs
Ruben Mesa • 23 Aug 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals